Competition in Weight Loss Drug Space: Eli Lilly's Obesity Drug Succeeds In Two Late-Stage Studies, Shows About 26% Weight Loss
Portfolio Pulse from Vandana Singh
Eli Lilly announced successful results from two phase 3 studies of its obesity drug, tirzepatide. The studies showed that participants achieved up to 26.6% mean weight loss. The safety profile was similar to previously reported trials and approved incretin-based therapies. The most common adverse events were mild to moderate gastrointestinal-related issues. Following the news, Eli Lilly's shares rose by 0.90%.
July 27, 2023 | 5:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's obesity drug, tirzepatide, showed promising results in phase 3 studies, leading to a 0.90% increase in the company's shares.
The successful results of the phase 3 studies of Eli Lilly's obesity drug, tirzepatide, are a positive development for the company. This could potentially lead to increased sales and revenue for Eli Lilly, which is reflected in the 0.90% increase in the company's shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100